Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures.

What Was Tested

This observational study looks at Glucagon in the context of low blood pressure and orthostatic hypotension.

Their aim was to investigate the association between endogenous GLP-1 responses to oral glucose and peripheral and central haemodynamic measures in a population at risk of diabetes and CVD.

Who Took Part

The abstract describes 837 individuals taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

All participants received an oral glucose tolerance test with measurements of GLP-1 at 0, 30 and 120 min.

How the Study Was Run

Aortic stiffness was assessed by pulse wave velocity (PWV).

The associations between GLP-1 response and central and brachial blood pressure (BP) and PWV were assessed in linear regression models adjusting for age and sex.

What Was Measured

The subject headings attached to it are Biomarkers, Blood Pressure, Brachial Artery, Cardiovascular Diseases, Cross-Sectional Studies, Denmark and Diabetes Mellitus.

The authors tagged it with the keywords Aortic stiffness, Central blood pressure, GLP-1 and Peripheral blood pressure.

What This Means in Plain Language

This is an observational study of Glucagon in 837 individuals in people with low blood pressure and orthostatic hypotension.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Cardiovascular diabetology), a journal based in England.

More context: the Glucagon compound page, Low blood pressure and orthostatic hypotension research.